​
​

Zentalis Pharmaceuticals (ZNTL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ZNTL Stock Forecast

Zentalis Pharmaceuticals stock forecast is as follows: an average price target of $21.86 (represents a 576.78% upside from ZNTL’s last price of $3.23) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

ZNTL Price Target

The average price target for Zentalis Pharmaceuticals (ZNTL) is $21.86 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $4.00. This represents a potential 576.78% upside from ZNTL's last price of $3.23.

ZNTL Analyst Ratings

Buy

According to 10 Wall Street analysts, Zentalis Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ZNTL stock is 0 'Strong Buy' (0.00%), 5 'Buy' (50.00%), 5 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Zentalis Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 18, 2024Akash TewariJefferies--39.37%85.76%
Jun 18, 2024Matthew HarrisonMorgan Stanley--93.24%147.68%
Jun 18, 2024Bradley CaninoStifel Nicolaus--85.53%209.60%
Jun 18, 2024Robert DriscollWedbush---29.82%23.84%
May 07, 2024Bradley CaninoStifel Nicolaus--157.44%890.71%
Nov 14, 2022Wedbush--41.84%890.71%
Nov 11, 2022Morgan Stanley--163.16%1602.79%
Nov 11, 2022Guggenheim--31.15%766.87%
Aug 10, 2022Leerink Partners--38.11%1200.31%
Aug 10, 2022H.C. Wainwright--80.86%1602.79%
Row per page
Go to

The latest Zentalis Pharmaceuticals stock forecast, released on Jun 18, 2024 by Akash Tewari from Jefferies, set a price target of $6.00, which represents a 39.37% increase from the stock price at the time of the forecast ($4.30), and a 85.76% increase from ZNTL last price ($3.23).

Zentalis Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts--5
Avg Price Target--$12.00
Last Closing Price$3.23$3.23$3.23
Upside/Downside-100.00%-100.00%271.52%

In the current month, the average price target of Zentalis Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Zentalis Pharmaceuticals's last price of $3.23. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024Cowen & Co.BuyBuyHold
Sep 16, 2024OppenheimerOutperformOutperformHold
Aug 12, 2024WedbushHoldNeutralUpgrade
Jun 20, 2024UBSNeutralDowngrade
Jun 18, 2024JefferiesHoldDowngrade
Jun 18, 2024Morgan StanleyEqual-WeightHoldDowngrade
Jun 18, 2024Morgan StanleyOverweightEqual-WeightDowngrade
Jun 18, 2024H.C. WainwrightBuyBuyHold
Jun 18, 2024WedbushUnderperformHoldDowngrade
Jun 18, 2024WedbushOutperformUnderperformDowngrade
Row per page
Go to

Zentalis Pharmaceuticals's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave ZNTL a "Buy" rating, the same as its previous rate.

Zentalis Pharmaceuticals Financial Forecast

Zentalis Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 20
Revenue---------
Avg Forecast-------$15.00M$100.00K
High Forecast-------$15.00M$100.00K
Low Forecast-------$15.00M$100.00K
# Analysts-------42
Surprise %---------

Zentalis Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ZNTL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Zentalis Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 20
# Analysts-------42
EBITDA--------$-15.92M
Avg Forecast--------$-31.13M
High Forecast--------$-24.91M
Low Forecast--------$-37.36M
Surprise %--------0.51%

undefined analysts predict ZNTL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Zentalis Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Zentalis Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 20
# Analysts-------42
Net Income--------$-16.13M
Avg Forecast$-54.61M$-54.90M$-56.04M$-55.27M$-56.20M$-39.86M$-59.73M$-54.56M$-30.69M
High Forecast$-54.61M$-54.90M$-56.04M$-46.06M$-44.69M$-39.86M$-59.73M$-54.56M$-24.55M
Low Forecast$-54.61M$-54.90M$-56.04M$-70.15M$-68.39M$-39.86M$-59.73M$-54.56M$-36.82M
Surprise %--------0.53%

Zentalis Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ZNTL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Zentalis Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 20
# Analysts-------42
SG&A--------$3.14M
Avg Forecast---------
High Forecast---------
Low Forecast---------
Surprise %---------

Zentalis Pharmaceuticals's average Quarter SG&A projection for Mar 24 is -, based on 4 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ZNTL last annual SG&A of $3.14M (Mar 20).

Zentalis Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 20
# Analysts-------42
EPS--------$-0.49
Avg Forecast$-0.77$-0.77$-0.79$-0.78$-0.79$-0.56$-0.84$-0.77$-0.70
High Forecast$-0.77$-0.77$-0.79$-0.65$-0.63$-0.56$-0.84$-0.77$-0.70
Low Forecast$-0.77$-0.77$-0.79$-0.99$-0.96$-0.56$-0.84$-0.77$-0.70
Surprise %--------0.70%

According to undefined Wall Street analysts, Zentalis Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ZNTL previous annual EPS of $NaN (undefined).

Zentalis Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ZNTLZentalis Pharmaceuticals--576.78%Buy
LIFEaTyr Pharma--478.95%Buy
INZYInozyme Pharma--422.06%Buy
ITOSiTeos Therapeutics--352.76%Buy
OLMAOlema Pharmaceuticals--224.60%Buy
SANASana Bio--206.51%Buy
DAWNDay One Biopharmaceuticals--182.80%Buy
ANNXAnnexon--172.37%Buy
CGEMCullinan Oncology--151.20%Buy
ERASErasca--140.74%Buy
SNDXSyndax Pharmaceuticals--113.18%Buy
DSGNDesign Therapeutics--72.06%Buy
PTGXProtagonist Therapeutics--18.38%Buy
BPMCBlueprint Medicines--16.53%Buy
KYMRKymera Therapeutics--14.50%Buy
RVMDRevolution Medicines, Inc. Warrant--6.84%Buy
VECTVectivBio--6.70%Buy
GRCLGracell Bio---41.46%Buy

ZNTL Forecast FAQ

Is Zentalis Pharmaceuticals a good buy?

Yes, according to 10 Wall Street analysts, Zentalis Pharmaceuticals (ZNTL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 50.00% of ZNTL's total ratings.

What is ZNTL's price target?

Zentalis Pharmaceuticals (ZNTL) average price target is $21.86 with a range of $4 to $55, implying a 576.78% from its last price of $3.23. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Zentalis Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for ZNTL stock, the company can go up by 576.78% (from the last price of $3.23 to the average price target of $21.86), up by 1602.79% based on the highest stock price target, and up by 23.84% based on the lowest stock price target.

Can Zentalis Pharmaceuticals stock reach $5?

ZNTL's average twelve months analyst stock price target of $21.86 supports the claim that Zentalis Pharmaceuticals can reach $5 in the near future.

What are Zentalis Pharmaceuticals's analysts' financial forecasts?

Zentalis Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $15M (high $15M, low $15M), average EBITDA is $0 (high $0, low $0), average net income is $-210M (high $-199M, low $-223M), average SG&A $0 (high $0, low $0), and average EPS is $-2.959 (high $-2.797, low $-3.13). ZNTL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-221M (high $-212M, low $-236M), average SG&A $0 (high $0, low $0), and average EPS is $-3.105 (high $-2.976, low $-3.315).